CPI-613 (devimistat)
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for CPI-613 (devimistat), covering 2018-07-02 to 2025-05-02. Get the full timeline:
Most recent: Clinical Trial Update: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma [Phase 2]